CSL and Alentis have announced a global partnership to collaborate on the development and commercialization of Lixudebart, a treatment for...
-
-
Recent Updates
- Global Collaboration Between CSL and Alentis to Develop and Commercialize Lixudebart for Treating Rare Kidney and Liver Diseases
- Huawei-Qualcomm Partnership Strengthens Technology Agreements
- Japan Inc’s Withdrawal from China Creates Opportunities for India
- Challenges and Opportunities: The Impact of Carbon Tariffs on Global Value Chains
- EU Proposes Countermeasures to Address China’s Trade Distortions
- Shanghai Tower: China’s bold megaproject
- Southeast Asia Grapples with Challenges as ‘China Plus One’ Strategy Falls Short
- UK to Impose Import Taxes on Chinese Cars, Impacting 5 Major Brands
- Chinese Electric Vehicle Sales Surge in UK Set to Shift Tariff Impositions
- China’s Rising Influence: Sterlite Tech Stock Surges 1,050% amid Global Expansion Predictions
Blogroll